LUCD - Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on March 26 2024
PR Newswire
Conference Call and Webcast at 8:30AM Eastern Time
NEW YORK , March 12, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), today announced that it will host a business update conference call and webcast on Tuesday, March 26, 2024 , at 8:30 AM ET . During the call, Lishan Aklog , M.D. , Lucid's Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company's operations and continued growth strategy. In addition, Dennis McGrath , Lucid's Chief Financial Officer, will discuss the Company's fourth-quarter and full year 2023 financial results.
The webcast will be available at the investor relations section of the Company's website at luciddx.com . Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name "Lucid Diagnostics Business Update" to join.
Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at luciddx.com .
About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage medical diagnostics company focused on cancer prevention, and subsidiary of PAVmed Inc. ( Nasdaq : PAVM ). Lucid is focused on the millions of patients with gastroesophageal reflux disease ( GERD ), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard ® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck Esophageal Cell Collection Device, is the first and only commercially available diagnostic test capable of serving as a widespread screening tool for at-risk patients to mitigate the risks of cancer and cancer deaths through early detection of esophageal precancer .
For more information, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com .
SOURCE Lucid Diagnostics
Company Name: | Lucid Diagnostics Inc. |
Stock Symbol: | LUCD |
Market: | NASDAQ |
News, Short Squeeze, Breakout and More Instantly...
Market Wire News is a media platform, the information on this page was provided by PR Newswire via Quote Media. Read our full disclaimer.